Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Fig. 1

CD19/CD22 antigen expression identified by flow cytometry. A, B, C Representatives of CD19 expression on lymphoblasts before hCD19 CAR-T therapy in 3 patients (Pt.). Samples were from bone marrow (BM) or tissue (Pt.12 relapsed with extramedullary disease only and without BM involvement). D Partial CD22 expression in Pt.18 who failed two mCD19 CAR-T therapies

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us